Covovax, developed by the Serum Institute of India in partnership with US-based Novavax, can be given to children aged 12-17, expanding from the FDA’s previous approval that allowed the vaccine to be administered to recipients aged over 18. The vaccine must be administered in two doses of 0.5 millilitres each, at an interval of three weeks, just like for adults.
